From the National Institutes of Health.
Healy
B
B
National Institutes of Health, Bethesda, MD 20892.
D036002:ADP Ribose Transferases; D000208:Acute Disease; D000658:Amoxicillin / Q000627:therapeutic use; D001145:Arrhythmias, Cardiac / Q000188:drug therapy*; D001427:Bacterial Toxins; D015704:CD4 Antigens; D009202:Cardiomyopathies / Q000139:chemically induced*; D002648:Child; D004317:Doxorubicin / Q000009:adverse effects*; D005098:Exotoxins; D015497:HIV-1 / Q000502:physiology*; D006801:Humans; D007223:Infant; D008214:Lymphocytes / Q000382:microbiology; D009000:Monocytes / Q000382:microbiology; D010033:Otitis Media / Q000188:drug therapy*; D011405:Propafenone / Q000627:therapeutic use; D011994:Recombinant Proteins; D037521:Virulence Factors; D000097668:Pseudomonas aeruginosa Exotoxin A
D036002:ADP Ribose Transferases; D000658:Amoxicillin; D001427:Bacterial Toxins; D015704:CD4 Antigens; D004317:Doxorubicin; D005098:Exotoxins; D011405:Propafenone; D011994:Recombinant Proteins; D037521:Virulence Factors; D000097668:Pseudomonas aeruginosa Exotoxin A